The new non-steroidal anti-inflammatory
drug (
NSAID), N-(3-[3-(piperidinyl-methyl) phenoxy] propyl)-carbamoyl-methylthio]ethyl 1-(p-chlorobenzoyl) 5-methoxy-2-methyl-3-indolyl-acetate (
CP 331, CAS 127966-70-5), a compound with a structure of an
ester combining
indomethacin (IM) and a
histamine H2 antagonist, has been reported to have anti-inflammatory,
analgesic and
antipyretic effects. However, the influence of
CP-331 on the gastroduodenal mucosa was not fully investigated. Therefore this study was undertaken to investigate the effect of
CP-331 on the gastroduodenal mucosa membrane in rats. After single
oral drug administration, the UD50 value (50% ulcerogenic dose) of
CP-331 calculated from the incidence rate of
gastric ulcer was higher than 1000 mg/kg; that for IM was 5.2 mg/kg. Moreover it was examined whether
CP-331 had a preventive effect on
NSAID-induced gastric damage. The results showed that the co-administration of
CP-331 10-30 mg/kg prevented significantly the acute gastric mucosal injury caused by IM administration (20 mg/kg).
CP-331 with anti-inflammatory activity does not cause gastric injury, moreover, because of its preventing and
therapeutic effects on the damage to gastric mucous membrane induced by IM,
CP-331 might be useful in the treatment of gastropathy caused by
NSAID in clinic.